




Endotherapeutics
IMPROVING HEALTHCARE

ePORE EndoVE[®] Precision Interventional Endoscopy Treatment for Gastrointestinal Cancer

INNOVATIVE ELECTROPORATION FOR CANCER TREATMENT



MIRAI MEDICAL
Innovative Cancer Solutions


CE
APPROVED

MIRAI MEDICAL has developed an endoscopic approach to target gastrointestinal cancers by utilizing an energy-based technology called **electroporation**. This treatment approach essentially causes tumour tissue to become extremely porous for several minutes allowing for greater absorption of specific chemotherapy drugs.

Of great benefit, due to the greater conductivity of tumour tissue, the surrounding **healthy tissue structures are not damaged in the process.**


Electroporation with chemotherapy has been in clinical use for more than 15 years and in 2006 the European Standard Operating Procedure (ESOPE) which described the standard delivery of the procedure including chemotherapy dose.

The effectiveness of electroporation in tumour ablation clinically has been reported by a growing number of clinicians in the US and Europe with excellent quality of life and tumour reduction reported for both cutaneous and intraluminal applications.



- Simple to use
- Touch screen
- Automatic recognition of electrode
- Standard generator for all electrodes

HOW ELECTROPORATION WORKS



EndoVE®



ADVANTAGES

- Precision delivery of non-thermal ablation which targets tumour tissue whilst preserving surrounding healthy tissue structures.
 - ePORE and EndoVE® are repeatable and leave standard treatment options available.
 - Delivered under light sedation, day case, cost effective.
- Simple standard connection for endoscopes between 9mm and 10mm
 - Connects to a vacuum which draws the tumour tissue into the chamber this can be viewed via the window at the head of the electrode.
 - Ease of use.

The procedure is similar to a standard endoscopy and is performed under sedation. A single low dose of the chemotherapy drug (bleomycin or cisplatin) is provided via intratumoural injection. Calcium has also now been demonstrated to be as effective when injected intratumourally and can be used to replace the chemotherapy drug.

The EndoVE® system delivers electroporation pulses directly to the tumour tissue via the ePORE generator with the process repeated several times until the entire tumour surface area and surrounding margins have been treated.

Typically the total procedure takes 20 minutes. Once recovered, the patient will be monitored for several hours before being released on the same day.




CLINICAL EXPERIENCE

The EndoVE® system has been assessed in clinical trials for patients with inoperable colorectal and oesophageal cancer. The clinical evidence to date with electroporation has demonstrated its excellent efficacy in tumour treatment even in cases where tumours were previously unresponsive to chemotherapy or radiotherapy.


No evidence of perforation or other adverse events have been observed to date. The EndoVE® device has demonstrated excellent utility in resolving large circumferential tumours, which typically require two endoscopic sessions for treatment.

Future clinical trials are planned to establish use in the earlier stages of disease, in combination with non-chemotherapeutic agents e.g. Calcium. In addition Electroporation has demonstrated synergy with immunotherapy.

COLO RECTAL - T3N2 RECTAL CANCER




Pre treatment




Post treatment (3 months)

OESOPHAGEAL CANCER - T3 OESOPHAGEAL CANCER



Pre treatment

Post treatment (4 weeks)




Post treatment



INTERVENTIONAL ENDOSCOPY TREATMENT FOR GASTROINTESTINAL CANCER

Mirai Medical is an exciting next-generation cancer treatment company bringing a ground-breaking new cancer solution to patients and clinicians.



References

- [1] Larkin JO, Collins CG, O'Reily S, Soden DM, O'Sullivan GC. Electrochemotherapy: aspects of preclinical development and early clinical experience. *Ann Surg.* 2007; 245(3):469-79.
- [2] Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality –clinical implications. *Technol Cancer Res Treat* 2007 6: 37–48.
- [3] Marty M et al. Electrochemotherapy - an easy, highly effective treatment of cutaneous and subcutaneous metastases: results of the ESOPE of Electrochemotherapy study. *Eur J Cancer Supplements* 2006 4: 3–13.
- [4] Cheung W, et al. Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience and Review of Safety and Outcomes. *Technol Cancer Res Treat.* 2013 Jan 25
- [5] Soden DM, et al. Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours. *Cancer Lett.* 2006 8;232(2):300-10
- [6] Forde, P, Sadadcharam M, Bourke M, Soden DM. Preclinical evaluation of an endoscopic electroporation system. *Endoscopy* 2016; 48; 477-483.
- [7] Egeland et al. Endoscopic electrochemotherapy for esophageal cancer – a phase I clinical study. 2018 *Endoscopy International*. In press.

CONTACT US

Mirai Medical Ltd.

Unit 5 | Howley Court | Oranmore | Co. Galway | Republic of Ireland

Telephone: 00 353 21 2340071

Email: info@mirai-medical.com

www.mirai-medical.com

Proudly distributed by



Endotherapeutics
IMPROVING HEALTHCARE

1300 00 ENDO

info@endotherapeutics.com.au

endotherapeutics.com.au

Suite 301, 2 Banfield Road
Macquarie Park NSW 2113